ACORN CAPITAL ADVISORS, LLC
CIK: 0002054410Latest portfolio: $295.1M · Q4 2025
Holdings
21
Total Value
$295.1M
New Positions
1
Closed Positions
0
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | TERNTERNS PHARMACEUTICALS INC | 1,746,264 | $70.5M | 23.90% | -225,000 | |
| 2 | CGONCG ONCOLOGY INC | 1,131,501 | $47.0M | 15.92% | — | |
| 3 | URGNUROGEN PHARMA LTD | 1,448,420 | $33.9M | 11.49% | +189K | |
| 4 | TRVITREVI THERAPEUTICS INC | 2,144,844 | $26.9M | 9.10% | — | |
| 5 | PBYIPUMA BIOTECHNOLOGY INC | 4,131,299 | $24.6M | 8.33% | — | |
| 6 | CADLCANDEL THERAPEUTICS INC | 2,580,517 | $14.6M | 4.94% | — | |
| 7 | HELPCYBIN INC | 1,573,023 | $12.9M | 4.36% | +839K | |
| 8 | VSTMVERASTEM INC | 1,469,153 | $11.3M | 3.84% | +690K | |
| 9 | BCAXBICARA THERAPEUTICS | 643,382 | $10.8M | 3.67% | — | |
| 10 | TARAPROTARA THERAPEUTICS INC | 1,752,115 | $9.3M | 3.16% | — | |
| 11 | OKURONKURE THERAPEUTICS INC | 2,839,674 | $8.2M | 2.79% | — | |
| 12 | CRDFCARDIF ONCOLOGY INC | 1,962,084 | $5.5M | 1.87% | — | |
| 13 | LONAATHIRA PHARMA INC. | 501,739 | $3.8M | 1.29% | NEW | |
| 14 | JSPRJASPER THERAPEUTICS | 1,786,492 | $3.3M | 1.11% | +404K | |
| 15 | AURAAURA BIOSCIENCES INC | 595,744 | $3.2M | 1.10% | — | |
| 16 | WHWKWHITEHAWK THERAPEUTICS INC | 1,139,363 | $2.8M | 0.93% | — | |
| 17 | BCABBIOATLA INC | 4,835,111 | $2.8M | 0.93% | — | |
| 18 | QTTBQ32 BIO INC. | 493,425 | $1.6M | 0.56% | -310,000 | |
| 19 | ASNSUSDX4 PHARMACEUTICALS INC | 273,349 | $1.1M | 0.37% | — | |
| 20 | ACRVACRIVON THERAPEUTICS INC | 405,237 | $976K | 0.33% | — | |
| 21 | VYNEVYNE THERAPEUTICS INC | 1,425 | $0 | 0.00% | -585,147 |
Quarterly Changes
New Positions
- LONANEW$3.8M
Closed Positions
No closed positions this quarter
Sector Breakdown
Healthcare0.0% ($7.054946979339213e+75T)
Unknown0.0% ($1.1M)
Filing History
Fund Information
ACORN CAPITAL ADVISORS, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $295.1M across 21 holdings. The largest position is TERNS PHARMACEUTICALS INC (TERN), representing 23.9% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 0 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.